METROPOLITAN LIFE INSURANCE CO/NY - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

Quarter-by-quarter ownership
METROPOLITAN LIFE INSURANCE CO/NY ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$140,408
-26.3%
6,806
+5.5%
0.01%
-22.2%
Q2 2023$190,399
+36.9%
6,452
+6.9%
0.01%
+28.6%
Q1 2023$139,092
-25.6%
6,037
-10.2%
0.01%
-12.5%
Q4 2022$187,022
+2.5%
6,725
+13.1%
0.01%
-11.1%
Q3 2022$182,452
+4.3%
5,9450.0%0.01%
+12.5%
Q2 2022$174,961
-2.5%
5,945
+6.6%
0.01%
+33.3%
Q1 2022$179,476
-83.3%
5,579
-76.8%
0.01%
-60.0%
Q4 2021$1,074,369
-11.6%
24,0890.0%0.02%
-16.7%
Q3 2021$1,215,290
-37.5%
24,089
-2.9%
0.02%
-33.3%
Q2 2021$1,945,077
+99.0%
24,797
+44.9%
0.03%
+80.0%
Q1 2021$977,381
-34.6%
17,117
-4.1%
0.02%
-31.8%
Q4 2020$1,495,451
+133.8%
17,8540.0%0.02%
+100.0%
Q3 2020$639,709
+36.3%
17,854
-8.0%
0.01%
+37.5%
Q2 2020$469,382
+70.9%
19,412
+23.8%
0.01%
+33.3%
Q1 2020$274,644
+4.1%
15,685
+3.5%
0.01%
+50.0%
Q4 2019$263,896
+13.7%
15,1490.0%0.00%0.0%
Q3 2019$232,083
-26.2%
15,1490.0%0.00%
-20.0%
Q2 2019$314,493
-10.6%
15,1490.0%0.01%
-16.7%
Q1 2019$351,760
+12.4%
15,1490.0%0.01%0.0%
Q4 2018$312,978
-5.0%
15,1490.0%0.01%0.0%
Q3 2018$329,339
-99.8%
15,149
+72.8%
0.01%
+200.0%
Q1 2018$172,662,0008,7690.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Crestline Management, LP 19,462,500$298,165,00048.02%
Bratton Capital Management, L.P. 953,035$14,600,00028.53%
Flagship Pioneering Inc. 8,005,747$122,648,0006.71%
Casdin Capital, LLC 650,000$9,958,000,0001.03%
Temasek Holdings (Private) Ltd 4,410,457$67,568,0000.50%
MARK ASSET MANAGEMENT LP 68,864$1,055,0000.26%
IRONWOOD INVESTMENT MANAGEMENT LLC 22,507$345,0000.26%
Artal Group S.A. 400,000$6,128,0000.25%
PIER 88 INVESTMENT PARTNERS LLC 40,610$622,0000.24%
HAMILTON LANE ADVISORS LLC 30,948$474,0000.20%
View complete list of DENALI THERAPEUTICS INC shareholders